CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression

被引:82
作者
Reynes, J
Portales, P
Segondy, M
Baillat, V
André, P
Avinens, O
Picot, MC
Clot, J
Eliaou, JF
Corbeau, P
机构
[1] Hop St Eloi, Immunol Lab, F-34295 Montpellier 5, France
[2] Hop St Eloi, Virol Lab, F-34295 Montpellier, France
[3] Hop Gui De Chauliac, Serv Malad Infect & Trop, Montpellier, France
[4] Hop Arnaud Villeneuve, Dept Med Informat, Montpellier, France
[5] Inst Genet Humaine, Montpellier, France
关键词
AIDS/HIV; CCR5; CD4 cell slope; chemokine receptor; long-term non-progressor; prognostic factor; T lymphocytes;
D O I
10.1097/00002030-200109070-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective and design: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression. Methods: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined. Results: CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomtic and non-treated, we observed a correlation between CCR5 density on HLA-DR-CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002). Conclusion: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:1627 / 1634
页数:8
相关论文
共 16 条
[1]   LONG-TERM HIV-1 INFECTION WITHOUT IMMUNOLOGICAL PROGRESSION [J].
BUCHBINDER, SP ;
KATZ, MH ;
HESSOL, NA ;
OMALLEY, PM ;
HOLMBERG, SD .
AIDS, 1994, 8 (08) :1123-1128
[2]   NON-PROGRESSION IN HIV-INFECTION [J].
EASTERBROOK, PJ .
AIDS, 1994, 8 (08) :1179-1182
[3]   Differential tropism and chemokine receptor expression of human immunodeficiency virus type 1 in neonatal monocytes, monocyte-derived macrophages, and placental macrophages [J].
Fear, WR ;
Kesson, AM ;
Naif, H ;
Lynch, GW ;
Cunningham, AL .
JOURNAL OF VIROLOGY, 1998, 72 (02) :1334-1344
[4]  
Husman AD, 1999, J IMMUNOL, V163, P4597
[5]   Frequency of CCR5 genotypes in HIV-infected patients in Roraima, Brazil [J].
Guerra Corado, Andre de Lima ;
Villarouco da Silva, George Allan ;
Carvalho Leao, Renato Augusto ;
Granja, Fabiana ;
Naveca, Felipe Gomes .
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2016, 20 (03) :314-315
[6]   Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [J].
Mellors, JW ;
Rinaldo, CR ;
Gupta, P ;
White, RM ;
Todd, JA ;
Kingsley, LA .
SCIENCE, 1996, 272 (5265) :1167-1170
[7]   Host genetic influences on HIV-1 pathogenesis [J].
Michael, NL .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (04) :466-474
[8]   CCR5 expression correlates with susceptibility of maturing monocytes to human immunodeficiency virus type 1 infection [J].
Naif, HM ;
Li, S ;
Alali, M ;
Sloane, A ;
Wu, LJ ;
Kelly, M ;
Lynch, G ;
Lloyd, A ;
Cunningham, AL .
JOURNAL OF VIROLOGY, 1998, 72 (01) :830-836
[9]  
Ostrowski MA, 1998, J IMMUNOL, V161, P3195
[10]   Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals:: Association with low expression of CCR5 and high production of β-chemokines [J].
Paxton, WA ;
Liu, R ;
Kang, S ;
Wu, LJ ;
Gingeras, TR ;
Landau, NR ;
Mackay, CR ;
Koup, RA .
VIROLOGY, 1998, 244 (01) :66-73